OBJECTIVE: To evaluate how voiding function and quality of life (QoL) were affected by transrectal ultrasound-guided prostate biopsy with respect to prostatic size and to determine whether there is a size-bothersomeness relationship. METHODS: Ninety-two patients who were candidates for prostate biopsy were included. Ten-core prostate biopsies were taken, and patients were followed up for 7 days. The international prostate symptom score, QoL, maximum urine flow rate (Q-max) and average urine flow rate, postvoid residual urine, and prostate volume (Vp) of the patients were recorded at baseline and on postbiopsy day 7. On receiver operating characteristics curve analysis, a Vp of 38.8 mL was found to be the best cutoff point for deterioration in QoL after biopsy. Then, patients were divided into 2 groups according to baseline Vp, as <38.8 mL and ≥38.8 mL, group 1 and 2, respectively. Baseline and postbiopsy values were compared. RESULTS: One patient in group 1 and 5 in group 2 developed acute urinary retention after biopsy, but the difference was not significant (P >.05). Only Vp and Q-max of group 1 (P <.001 and P = .035, respectively), but QoL (P = .002), international prostate symptom score, Q-max, Vp (P <.001 in all 3), and average urine flow rate (P = .006) of group 2 were significantly changed on postbiopsy day 7 compared with baseline. CONCLUSION: Patients with a Vp >38.8 mL were more prone to voiding difficulty and deterioration in QoL after biopsy. They should be informed about the likelihood of these complications.
OBJECTIVE: To evaluate how voiding function and quality of life (QoL) were affected by transrectal ultrasound-guided prostate biopsy with respect to prostatic size and to determine whether there is a size-bothersomeness relationship. METHODS: Ninety-two patients who were candidates for prostate biopsy were included. Ten-core prostate biopsies were taken, and patients were followed up for 7 days. The international prostate symptom score, QoL, maximum urine flow rate (Q-max) and average urine flow rate, postvoid residual urine, and prostate volume (Vp) of the patients were recorded at baseline and on postbiopsy day 7. On receiver operating characteristics curve analysis, a Vp of 38.8 mL was found to be the best cutoff point for deterioration in QoL after biopsy. Then, patients were divided into 2 groups according to baseline Vp, as <38.8 mL and ≥38.8 mL, group 1 and 2, respectively. Baseline and postbiopsy values were compared. RESULTS: One patient in group 1 and 5 in group 2 developed acute urinary retention after biopsy, but the difference was not significant (P >.05). Only Vp and Q-max of group 1 (P <.001 and P = .035, respectively), but QoL (P = .002), international prostate symptom score, Q-max, Vp (P <.001 in all 3), and average urine flow rate (P = .006) of group 2 were significantly changed on postbiopsy day 7 compared with baseline. CONCLUSION:Patients with a Vp >38.8 mL were more prone to voiding difficulty and deterioration in QoL after biopsy. They should be informed about the likelihood of these complications.